


PHARMACEUTICAL 2022

F-star Therapeutics Inc. Rank 167 of 475







PHARMACEUTICAL 2022

F-star Therapeutics Inc. Rank 167 of 475



The relative strengths and weaknesses of F-star Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of F-star Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 68% points. The greatest weakness of F-star Therapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is -29%, being 248% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	84,739
Cost of Goods Sold	0
Intangible Assets	33,663
Liabilities, Current	12,135
Liabilities, Non-Current	2,723
Other Assets	3,732
Other Compr. Net Income	-425
Other Expenses	-372
Other Liabilities	11,306
Other Net Income	-941
Property and Equipment	887
Research and Development	28,750
Revenues	21,167
Selling, General and Administrative Expense	23,131

Output Variable	Value in 1000 USD
Assets	123,021
Liabilities	26,164
Expenses	51,509
Stockholders Equity	96,857
Net Income	-31,283
Comprehensive Net Income	-31,496
Economic Capital Ratio	-29%